Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
TriSalus Life Sciences is a pre-revenue medical device company developing the Pressure-Enabled Drug Delivery (PEDD) platform for targeted cancer therapy delivery directly to tumors. The company's lead product, the TriNav Infusion System, enables precise delivery of chemotherapy and immunotherapy agents to liver tumors while minimizing systemic exposure. As a clinical-stage company with minimal revenue ($0.0M TTM), the stock trades on clinical trial milestones, regulatory pathway progress, and capital runway rather than traditional financial metrics.
TriSalus operates a razor-razorblade model where the TriNav catheter system (capital equipment) enables proprietary pressure-enabled drug delivery procedures. Revenue will derive from per-procedure disposable kits, with pricing power stemming from clinical differentiation in tumor drug concentration versus systemic toxicity. The 86.1% gross margin suggests manufacturing efficiency typical of catheter-based devices, though current margins reflect limited production scale. Competitive advantage lies in IP protection around pressure modulation technology and clinical data demonstrating superior drug penetration in solid tumors, particularly hepatocellular carcinoma and liver metastases.
Clinical trial data readouts from PEDD platform studies in liver cancer (ORR, PFS, safety profile versus standard of care)
FDA regulatory milestone announcements (IDE approval, breakthrough device designation, PMA submission/approval timeline)
Strategic partnerships or licensing deals with pharmaceutical companies for combination therapy trials
Capital raises and cash runway updates (current 3.05x current ratio suggests 12-18 months runway at current burn)
Competitive developments in interventional oncology space (TACE, Y90, hepatic artery infusion pump data)
FDA regulatory approval risk - PEDD platform represents novel mechanism requiring extensive clinical validation; PMA pathway typically takes 3-5 years with 20-30% historical approval rates for Class III devices
Reimbursement uncertainty - CMS and private payers must establish separate payment codes for PEDD procedures; inadequate reimbursement levels could limit commercial adoption despite clinical efficacy
Clinical trial execution risk - liver cancer trials face enrollment challenges, high dropout rates, and competing standard-of-care options (TACE, systemic therapy, transplant)
Established interventional oncology competitors (Boston Scientific, Terumo, Merit Medical) could develop competing pressure-modulated delivery systems or acquire TLSI's technology
Systemic immunotherapy advances (checkpoint inhibitors, CAR-T) may reduce addressable market for locoregional liver therapies
Alternative hepatic delivery technologies (hepatic artery infusion pumps, Y90 radioembolization improvements) compete for same patient population
Capital runway risk - $20-25M annual burn rate with $60-70M estimated cash (based on 3.05x current ratio) suggests need for financing by Q4 2026 or Q1 2027; dilution risk at depressed valuation
Negative equity position (148.8% ROE with negative earnings indicates negative book value) limits access to traditional debt financing
Going concern risk if clinical milestones slip or FDA requests additional studies requiring capital beyond current runway
low - Pre-revenue medical device companies are largely insulated from GDP fluctuations as they operate in clinical development phase. However, hospital capital equipment budgets for eventual commercial adoption show moderate correlation to healthcare system financial health. Cancer treatment demand is non-discretionary, providing defensive characteristics post-commercialization.
Rising interest rates create significant headwinds through multiple channels: (1) Higher discount rates compress NPV of future cash flows, disproportionately impacting long-duration assets like pre-revenue biotech; (2) Increased cost of capital for future financing rounds creates dilution risk; (3) Risk-off sentiment shifts capital away from speculative growth into safer assets. The -7.5x price/book and negative cash flow profile make TLSI highly sensitive to Fed policy and the 10-year Treasury yield as the risk-free rate benchmark.
Moderate - While the company has -1.28 debt/equity (suggesting net cash position or off-balance sheet items), future capital needs are substantial. Tightening credit conditions reduce availability of venture debt or convertible financing, forcing more dilutive equity raises. High-yield credit spreads serve as proxy for risk appetite in speculative healthcare names.
growth - Pure clinical-stage speculation attracting venture capital-style investors betting on binary FDA approval outcomes and potential 5-10x returns on successful commercialization. The -112.9% net margin, minimal revenue, and -18.9% one-year return indicate this is a high-risk/high-reward profile unsuitable for value or income investors. Momentum traders may play clinical catalyst events, but core holders are typically specialized healthcare funds with portfolio diversification across multiple clinical-stage names.
high - Pre-revenue medical device stocks exhibit 60-100% annualized volatility driven by binary clinical and regulatory events. The $200M market cap and limited float amplify price swings on news flow. Options market typically prices 80-120% implied volatility around data readouts. Three-month return of 1.3% versus six-month -0.2% shows choppy, event-driven trading pattern rather than sustained trends.
